The antiphospholipid syndrome (APS) refers to persistent antiphospholipid antibodies (aPL)
associated with thrombotic and/or obstetrical complications. The endothelial cell is a target …

The antiphospholipid syndrome is characterized by venous or arterial thrombosis and/or
recurrent fetal loss in the presence of circulating antiphospholipid antibodies. These …

Background The antiphospholipid syndrome (APS) is the association of thrombosis and
recurrent pregnancy loss and/or pregnancy morbidity with persistent antiphospholipid …

Microparticles (MPs) resulting from vesiculation of platelets and other blood cells have been
extensively documented in vitro and have been found in increased numbers in several …

Objectives: To study circulating platelet, monocyte and endothelial microparticles (PMPs,
MMPs and EMPs) in patients with antiphospholipid syndrome (APS) in comparison with …

The risk for thrombosis is significantly increased in systemic lupus erythematosus (SLE),
affecting both venous and arterial vessels. Activated platelets are known to participate in …

Background: Endothelial activation and dysfunction are associated with several diseases.
However, hardly any specific markers are available. Microparticles (MP) from endothelial …

Objectives: The purpose of this research was to determine the levels of platelet, leukocyte,
and endothelial activation and markers of cellular interactions in patients with venous …

INTRODUCTION: Microparticles from activated endothelial cells (EMP) are well known to
expose tissue factor (TF) and initiate coagulation in vitro. TF coagulant activity is critically …

Objective Antiphospholipid antibodies (aPL), especially those targeting β2‐glycoprotein I
(β2GPI), are well known to activate endothelial cells, monocytes, and platelets, with …